Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
03:00am, Monday, 25'th Aug 2025
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biogen (BIIB) To Contact Him Directly To Discuss Their Options
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
09:15am, Saturday, 02'nd Aug 2025
Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
02:24pm, Thursday, 31'st Jul 2025
Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
11:50am, Thursday, 31'st Jul 2025
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 31'st Jul 2025
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
08:20am, Thursday, 31'st Jul 2025
Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago.
Biogen raises annual profit forecast on strong demand for rare disease drugs
06:17am, Thursday, 31'st Jul 2025
Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
11:00am, Wednesday, 30'th Jul 2025
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:15am, Wednesday, 30'th Jul 2025
Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
08:12am, Wednesday, 30'th Jul 2025
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne
